Fig. 1From: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancerCUDC-907 induces cytotoxicity in a panel of SCLC cell lines. a Growth inhibition curves of CUDC-907 in a panel of SCLC cell lines. b Cell-cycle distribution of four SCLC cell lines following CUDC-907 treatment for 24 h by flow cytometry. c, d Western blot analysis of p21 (c), phospho-proteins downstream of PI3K and acetylated H3 (d) in SCLC cell lines upon treated with different concentrations of CUDC-907 for 24 hBack to article page